Fairmount Funds Management LLC Iovance Biotherapeutics, Inc. Transaction History

Fairmount Funds Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$20.35 - $26.63 $2.37 Million - $3.1 Million	-116,302 Reduced 22.99%	389,588 $9.61 Million
Q2 2021 Aug 13, 2021	SELL	$16.33 - $33.07 $979,799 - $1.98 Million	-60,000 Reduced 10.6%	505,890 $13.2 Million
Q4 2020 Feb 12, 2021	SELL	$28.04 - $50.26 $869,240 - $1.56 Million	-31,000 Reduced 5.19%	565,890 $26.3 Million
Q3 2020 Nov 12, 2020	SELL	$27.75 - $36.3 $194,250 - $254,099	-7,000 Reduced 1.16%	596,890 $19.7 Million
Q2 2020 Aug 04, 2020	BUY	$27.21 - $41.0 $3.06 Million - $4.61 Million	112,500 Added 22.89%	603,890 $16.6 Million
Q1 2020 May 08, 2020	BUY	$19.54 - $38.85 $732,750 - $1.46 Million	37,500 Added 8.26%	491,390 $14.7 Million
Q4 2019 Feb 12, 2020	BUY	$17.95 - $29.41 $8.15 Million - $13.3 Million	453,890 New	453,890 $12.6 Million

343

247M

2.51M

3.5M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $559M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

Stay updated on Fairmount Funds Management LLC with notifications on news.